@article{10673,
  keywords = {Canada/epidemiology, Cohort Studies, *Diabetes Mellitus, Type 2/drug therapy/epidemiology, *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor/agonists, Glucose, Humans, Hypoglycemic Agents/pharmacology/therapeutic use, Sodium, *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, *Symporters/therapeutic use, United Kingdom/epidemiology, Type 2 diabetes, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium-glucose co-transporter 2 inhibitors, not involving SGLT-2 inhibitors or DPP-4 inhibitors.},
  author = {V. Brunetti and A. St-Jean and S. Dell'Aniello and A. Fisher and O. H. Y. Yu and S. Bugden and J. Daigle and N. Hu and S. Alessi-Severini and B. Shah and P. Ronksley and L. Lix and P. Ernst and K. Filion},
  title = {Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom},
  year = {2022},
  journal = {BMC Endocr Disord},
  volume = {22},
  edition = {2022/09/30},
  number = {1},
  pages = {241},
  isbn = {1472-6823},
  doi = {10.1186/s12902-022-01140-1},
  note = {1472-6823
Brunetti, Vanessa C
St-Jean, Audray
Dell'Aniello, Sophie
Fisher, Anat
Yu, Oriana H Y
Bugden, Shawn C
Daigle, Jean-Marc
Hu, Nianping
Alessi-Severini, Silvia
Shah, Baiju R
Ronksley, Paul E
Lix, Lisa M
Ernst, Pierre
Filion, Kristian B
Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Journal Article
BMC Endocr Disord. 2022 Sep 29;22(1):241. doi: 10.1186/s12902-022-01140-1.},
  language = {eng},
}